DRTS (Alpha Tau Medical) Beta: 1.0384 (As of Jul. 05, 2026)


DRTS Alpha Tau Medical Ltd DRTS
28 GF Score
Price $13.22
! 3 Warning Signs
View Full Analysis

What is Alpha Tau Medical Beta?

Alpha Tau Medical DRTS +4.67% 28 Beta is 1.0384 as of Jul. 05, 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-05), Alpha Tau Medical's Beta is 1.0384.


Alpha Tau Medical  (NAS:DRTS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Alpha Tau Medical Beta Related Terms


Alpha Tau Medical Beta Historical Data

* Premium members only.

The historical data trend for Alpha Tau Medical's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Tau Medical Beta Chart

Alpha Tau Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 1.21

Alpha Tau Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 1.40 0.90 1.21 0.85

DRTS vs ORIC, OLMA, KURA: Beta Comparison

For the Biotechnology subindustry, Alpha Tau Medical's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Tau Medical Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Beta distribution charts can be found below:

* The bar in red indicates where Alpha Tau Medical's Beta falls into.


DRTS
28GF Score
Alpha Tau Medical Ltd DRTS
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Tau Medical Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.0384 mean?
Alpha Tau Medical (DRTS) has a Beta of 1.0384 as of Jul. 05, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Alpha Tau Medical and its competitors.
Is Alpha Tau Medical's Beta too high?
Alpha Tau Medical's current Beta is 1.0384. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Beta compare to ORIC and OLMA?
Alpha Tau Medical's Beta of 1.0384 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Alpha Tau Medical and its competitors. Alpha Tau Medical's current Beta is 1.0384. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Beta of 1.0384. The current Beta is 1.0384. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Beta is 1.0384 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Tau Medical Business Description

Address Kiryat HaMada Street 5, Jerusalem, ISR, 9777605
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score

Get the complete analysis for DRTS

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.22
Price